Jie Dong
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers 13
- CAR-T cell therapy research 12
- Pancreatic and Hepatic Oncology Research 9
- Cancer Cells and Metastasis 8
- Immunology top 5%
- Immunotherapy and Immune Responses 9
- Cancer Research top 5%
- Dermatology top 5%
- Molecular Biology top 10%
- RNA modifications and cancer 9
-
- Virus-based gene therapy research 13
-
- Esophageal Cancer Research and Treatment 9
- Cited by
- OncologyImmunologyCancer Research
- Partner nations
- ChinaUnited StatesMacao
In The Last Decade
Jie Dong
118 papers receiving 3.0k citations
Peers
Comparison fields: 5 of 127
- Oncology 1.0k
- Immunology 774
- Cancer Research 523
- Dermatology 148
- Molecular Biology 1.1k
Countries citing papers authored by Jie Dong
This map shows the geographic impact of Jie Dong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jie Dong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jie Dong more than expected).
Fields of papers citing papers by Jie Dong
This network shows the impact of papers produced by Jie Dong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jie Dong. The network helps show where Jie Dong may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jie Dong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 9 | |
| 5 | 2024 | 2 | |
| 6 | 2023 | 0 | |
| 7 | 2022 | 5 | |
| 8 | 2022 | 5 | |
| 9 | 2022 | 7 | |
| 10 | 2021 | 3 | |
| 11 | 2021 | 3 | |
| 12 | 2021 | 24 | |
| 13 | 2019 | 43 | |
| 14 | 2019 | 7 | |
| 15 | Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses | 2018 | 1 |
| 16 | 2018 | 49 | |
| 17 | 2015 | 4 | |
| 18 | 2015 | 51 | |
| 19 | 2013 | 16 | |
| 20 | 2010 | 18 |
About Jie Dong
Jie Dong is a scholar working on Oncology, Immunology and Cancer Research, having authored 125 papers that have together received 3.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (13 papers), Virus-based gene therapy research (13 papers), CAR-T cell therapy research (12 papers), Pancreatic and Hepatic Oncology Research (9 papers), RNA modifications and cancer (9 papers), Esophageal Cancer Research and Treatment (9 papers), Immunotherapy and Immune Responses (9 papers) and Cancer Cells and Metastasis (8 papers). The work is most often cited by research in Oncology (1.0k citations), Immunology (774 citations) and Cancer Research (523 citations). Jie Dong has collaborated with scholars based in China, United States and Macao. Frequent co-authors include Jiwu Wei, Chun Kwok Wong, Shuguang Zuo, Shiqun Wang, Min Wei, Zhe Cai, Delong Jiao, Yi Li, Man Chu and Junhua Wu.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.